Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMOX2 | P30519 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6299525 | 1.00 | HMOX2 (0.50) | HMOX2FAAHMGLLCYP19A1TBXAS1 | |
| SCHEMBL22047552 | 0.76 | TBXAS1 (0.46) | HMOX2FAAHMGLLTBXAS1 | |
| SCHEMBL15099355 | 0.74 | FAAH (0.54) | HMOX2FAAHMGLLCYP19A1TBXAS1 | |
| SCHEMBL10613945 | 0.74 | CYP19A1 (0.47) | FAAHMGLLCYP19A1TBXAS1 | |
| SCHEMBL1260765 | 0.73 | FAAH (0.52) | HMOX2FAAHMGLLCYP19A1TBXAS1 | |
| SCHEMBL9033220 | 0.73 | SMN1; SMN2 (0.50) | HMOX2FAAHMGLL | |
| SCHEMBL10584100 | 0.72 | CYP19A1 (0.49) | HMOX2FAAHMGLLCYP19A1 | |
| SCHEMBL1260766 | 0.72 | TBXAS1 (0.50) | CYP19A1TBXAS1 | |
| SCHEMBL28565013 | 0.72 | ALDH1A1 (0.54) | FAAHMGLLCYP19A1TBXAS1KDM4E | |
| SCHEMBL25635684 | 0.72 | TBXAS1 (0.37) | HMOX2FAAHMGLLTBXAS1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6943183-B2 | 5-substituted tetralones as inhibitors of ras farnesyl transferase | PFIZER INC (US) | 2005-09-13 | — | — | US | disclosed |
| US-20040044057-A1 | 5- substituted tetralones as inhibitors of ras farnesyl trransferase | WARNER-LAMBERT COMPANY | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044057-A1 | 5- substituted tetralones as inhibitors of ras farnesyl trransferase | PTAR1, FNTA, GGPS1 | HMOX2 4054/4885FAAH 603/4885MGLL 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.